Filing summary
Entity and period: The supplied filing is Trovagene, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, filed March 15, 2017. This does not match the request metadata identifying Cardiff Oncology, Inc. or a standalone 2016 Q4 filing. The summary below covers Trovagene’s full fiscal year; quarterly data are noted where relevant.
Business context and reporting period
Trovagene was a development-stage molecular diagnostics company focused on detecting and monitoring circulating tumor DNA in urine and blood using its Precision Cancer Monitoring technology. It offered Trovera laboratory-developed tests through its San Diego CLIA/CAP-accredited laboratory and was developing research-use-only kits and systems. Management announced a strategic shift toward kit and system distribution, while continuing selected clinical testing services.
Key financial metrics
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $381,000 | $313,000 |
| Operating expenses | $40.5 million | $25.6 million |
| Operating loss | $40.1 million | $25.3 million |
| Net loss attributable to common stockholders | $39.2 million | $27.5 million |
| Basic net loss per share | $1.30 | $1.05 |
| Cash used in operating activities | $31.0 million | $22.1 million |
| Cash and cash equivalents | $13.9 million | $67.5 million |
| Short-term investments | $24.0 million | None reported |
| Working capital | $31.2 million | $60.2 million |
| Total assets | $44.0 million | $71.4 million |
| Stockholders’ equity | $19.8 million | $48.7 million |
- Diagnostic-service and clinical-research revenue rose, but royalties declined slightly. Revenue remained very small relative to the company’s costs.
- Cost of revenue was $1.73 million against total revenue of $381,000, implying a negative gross margin. The filing attributes this to the cost and operating inefficiencies of building test volume; revenue recognition on services was generally tied to cash collection.
- Research and development expense increased to $15.0 million from $10.6 million; selling and marketing rose to $11.5 million from $6.4 million; general and administrative expense rose to $11.5 million from $7.9 million.
- Year-end debt carrying amounts were approximately $16.5 million, before considering the distinction between carrying value and contractual principal, fees, and interest. Debt was variable-rate and subject to covenants. Contractual debt obligations, including interest, were reported at $20.5 million.
- A $2.46 million non-cash gain from revaluing warrant liabilities reduced the reported net loss; the warrant liability fell to $835,000 from $3.30 million.
- For Q4 2016, revenue was $68,000 and net loss attributable to common stockholders was $8.55 million.
Material changes versus the prior comparable period
- Revenue increased by approximately $68,000, while operating expenses rose by approximately $14.9 million and net loss attributable to common stockholders widened by approximately $11.7 million.
- Operating cash use increased by approximately $8.9 million. Cash and cash equivalents fell substantially, although the company held $24.0 million in short-term investments at year-end; combined cash and short-term investments were approximately $37.9 million.
- Research and development and commercial spending expanded during the year. A December 2016 restructuring incurred approximately $790,000 in charges, including employee termination costs and impairment of an abandoned software project.
- The company raised approximately $2.3 million net through common-stock sales in 2016, compared with approximately $61.2 million from public offerings in 2015.
Outlook, commentary, risks and unusual items
- Management expected the company’s available capital to support operations for the next 12 months, but said additional funding would be needed beyond that period until operations generate sufficient cash. It warned that financing may not be available on acceptable terms and could dilute shareholders or impose restrictive covenants.
- On March 15, 2017, after year-end, the company announced a restructuring expected to reduce annual pre-tax expenses by approximately $8 million, excluding one-time separation costs, through a reduction of about 30 employees and lower research, clinical-study and operating costs.
- Also after year-end, Trovagene licensed global development and commercialization rights to investigational oncology drug PCM-075. The agreement included a $2 million upfront payment, future development and regulatory milestones, and royalties. This marked an expansion into therapeutics; the filing does not provide a quantified forecast for its financial impact.
- Commercialization depends on clinical validation, physician and payer acceptance, reimbursement, manufacturing and distribution execution, and regulatory requirements. The company had not filed for FDA approval of its proposed products and described potential changes to regulation of laboratory-developed tests as a risk.
- Other significant risks include ongoing losses, need for capital, competition, variable-rate secured debt and covenant restrictions, reliance on one primary laboratory, intellectual-property challenges, and dilution. A third party had opposed claims in a European patent; the company was considering its response.
- Trovagene and its former CEO and CFO were in litigation over an alleged corporate opportunity; the former executives had filed a cross-complaint. The parties were in discovery. The filing also disclosed possible federal and state tax exposures relating to past executive compensation, with no liability accrued.
- The company reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Confirm the entity and period: this is Trovagene’s FY 2016 10-K, not a Cardiff Oncology filing or a standalone Q4 report.
- Review the full audited statements and debt notes, including repayment schedule, variable interest rates, collateral, covenants, and final-payment obligations.
- Assess cash runway using the combined cash and investment balance, ongoing operating cash burn, and management’s stated need for financing beyond 12 months.
- Track whether the announced expense reductions are realized and how the strategic shift and PCM-075 license affect spending, milestones, and financing needs.
- Verify clinical evidence, regulatory status, reimbursement coverage, and commercial uptake; reported study findings and market estimates do not establish future sales or profitability.
- Monitor the former-executive litigation, the patent opposition, and the disclosed potential tax exposure.